Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®) (2mg) Over a 12-week Period for Patients Suffering From Neovascular Age-related Macular Degeneration (AMD) French SD OCT in wAMD
Phase of Trial: Phase IV
Latest Information Update: 23 Nov 2016
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 18 Nov 2016 Status changed from recruiting to completed.
- 22 Oct 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 08 Oct 2014 New trial record